Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy
详细信息 查看全文
- 作者：Maurice Pé ; rola ; maurice.perol@lyon.unicancer.fr" class="auth_mail" title="E-mail the corresponding author ; Tudor-Eliade Ciuleanub ; tudor@iocn.ro" class="auth_mail" title="E-mail the corresponding author ; Oscar Arrietac ; cogar@servidor.unam.mx" class="auth_mail" title="E-mail the corresponding author ; Kumar Prabhashd ; kprabhash1@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Konstantinos N. Syrigose ; ksyrigos@med.uoa.gr" class="auth_mail" title="E-mail the corresponding author ; Tuncay Gokself ; tuncaygoksel@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Keunchil Parkg ; keunchil.park@samsung.com" class="auth_mail" title="E-mail the corresponding author ; Ruben Dario Kowalyszynh ; kowar@rnonline.com.ar" class="auth_mail" title="E-mail the corresponding author ; Joanna Pikieli ; joanna.pikiel@post.pl" class="auth_mail" title="E-mail the corresponding author ; Conrad R. Lewanskij ; Conrad.lewanski@imperial.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; Michael Thomask ; michael.thomas@med.uni-heidelberg.de" class="auth_mail" title="E-mail the corresponding author ; Shaker Dakhill ; shaker.dakhil@cancercenterofkansas.com" class="auth_mail" title="E-mail the corresponding author ; Joo-Hang Kimm ; kjhang@yuhs.ac" class="auth_mail" title="E-mail the corresponding author ; Nina Karasevan ; nkaraseva06@mail.ru" class="auth_mail" title="E-mail the corresponding author ; Sergey Yurasovo ; sergey.yurasov@imclone.com" class="auth_mail" title="E-mail the corresponding author ; Annamaria Zimmermannp ; q ; zimmermann_annamaria_hayden@lilly.com" class="auth_mail" title="E-mail the corresponding author ; Pablo Leer ; pablo.lee@imclone.com" class="auth_mail" title="E-mail the corresponding author ; Gebra Cuyun Carterp ; q ; Martin Reckr ; M.Reck@lungenclinic.de" class="auth_mail" title="E-mail the corresponding author ; Federico Cappuzzos ; f.cappuzzo@googlemail.com" class="auth_mail" title="E-mail the corresponding author ; Edward B. Garont ; egaron@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：ASBI ; Average Symptom Burden Index ; CI ; confidence interval ; ECOG ; Eastern Cooperative Oncology Group ; HR ; hazard ratio ; IQR ; interquartile range ; LCSS ; Lung Cancer Symptom Scale ; NSCLC ; non-small cell lung cancer ; PL ; + ; DTX ; placebo ; + ; docetaxel ; PS ; performance status ; QoL ; quality of life ; RAM ; + ; DTX ; ramucirumab ; + ; docetaxel ; SD ; standard deviation ; TtD ; time to deterioration
- 刊名：Lung Cancer
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：93
- 期：Complete
- 页码：95-103
- 全文大小：1451 K
文摘
- class="listitem" id="list_lis0005">
- class="label">•
Addition of ramucirumab to docetaxel in NSCLC post-platinum setting led to an improvement of overall survival in the REVEL study.
- class="label">•
This analysis examined quality of life as assessed by the Lung Cancer Symptom Scale (LCSS) and clinician-reported functional status.
- class="label">•
Time to deterioration for all LCSS scores and time to PS ≥2 were similar in both arms.
- class="label">•
Adding ramucirumab to docetaxel in NSCLC post-platinum setting did not impair patient quality of life, symptoms or functioning.